Another match point for the industry to maintain Geraniol as an active substance under the BPR
Regulatory clarity brings stability to the sector
The regulatory future of Geraniol in the European Union has gained renewed clarity following recent communication from the European Commission. According to information confirmed via DG SANTE, the active substance will continue to be assessed under the Biocidal Products Regulation (BPR) while ongoing legal proceedings remain unresolved. This development updates earlier uncertainty and provides a more stable outlook for the sector. The decision follows a challenge to the withdrawal request submitted by ANSES, which was primarily based on delays in submitting certain scientific data rather than concerns related to safety or efficacy.
Time to complete data and strengthen the dossier
The legal process is expected to last between two and three years, offering stakeholders valuable time to complete pending studies and close existing data gaps. This period is increasingly viewed as an opportunity to consolidate the scientific dossier and reinforce the evaluation process under the BPR. Industry representatives, including Terpenetech, emphasize that a fully completed dataset will allow Geraniol to be assessed on a stronger and more comprehensive basis. Previous publications have already highlighted its natural origin, as well as its dual function as a repellent and insecticidal agent, combined with a notably favorable toxicological profile.
Uses intended for Geraniol as an active substance:
- PT18 – Insecticides, acaricides and products to control other arthropods
- PT19 – Repellents and attractants
Market confidence and continued commercialization
From a commercial standpoint, the implications are significant for all actors involved in the value chain. Geraniol is no longer considered at immediate risk of withdrawal in the short term, which reassures laboratories, contract manufacturers, and distributors across Europe. Companies can continue to develop and market biocidal products based on this substance without disruption. For stakeholders who have invested consistently and strategically in Geraniol, this confirmation represents a positive turning point. While regulatory scrutiny under the BPR remains rigorous, the current outlook supports cautious optimism and reinforces the role of Geraniol as a key active ingredient in the European biocides market.
Do you need support to comply with the BPR Regulation? Nordiik can help, contact us!
Source: ECHA
